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We thank Dr Karim, MY for his interest in and kind comments on our study (1), in which we 
reported a low rate (i.e. 7 out of 700; 1%) of patients who required immunoglobulin 
replacement therapy (IGRT) for recurrent infections despite treatment with prophylactic 
antibiotics and/or hypogammaglobulinemia during rituximab (RTX) therapy in our cohort. 
This rate was the lowest compared to other published cohorts, which predominantly comprised 
patients with ANCA-associated vasculitis (AAV), ranging from 4–21% (2-4).  Indeed, this low 
rate of IGRT requirement in our cohort was contributed to the variability in the diagnoses of 
rheumatic and musculoskeletal diseases (RMDs) studied. Of 7 patients who required the IGRT 
in our cohort, the rates were higher in systemic lupus erythematosus (SLE) and AAV, 2/94 
(2.1%) and 1/49 (2.0%) respectively compared to rheumatoid arthritis (RA), 3/504 (0.6%). We 
believe that the higher rates for low IgG level (<6 g/L) at RTX initiation and subsequent 
requirement for IGRT during RTX therapy in SLE and AAV compared to RA were contributed 
by the intensity of previous remission induction agents including cyclophosphamide as 
depicted in Figure 1 of our paper (1). In comparison to cohorts from Roberts et al. (2, 5), Besada 
et al. (3) and Venhoff et al. (4) of which their rates for IGRT requirement for AAV indication 
were 8/288 (2.8%), 5/35 (14%) and 7/33 (21%), the low rate for IGRT requirement in our 
cohort was likely due to the difference in RTX retreatment strategy. We employed retreatment 
on clinical relapse (i.e. relapse was defined as an increase in the Birmingham Vasculitis 
Activity Score (BVAS) ≥1) compared to the fixed retreatment intervals i.e. every 6-12 months 
as per cohorts above. One concern using this re-treatment strategy was that allowing relapse 
might result in organ-threatening flares or necessitated exposure to further high dose of 
glucocorticoids.  However, we previously reported that re-treatment on clinical relapse was 
effective with no patients discontinued RTX therapy at 7 years due to loss of efficacy, disease 
activity at each subsequent relapse was less severe than that at RTX initiation, the mean daily 
 
oral prednisolone dose requirement was significantly reduced with more than a third of patients 
discontinued corticosteroid at the last follow-up, as well as none of our patient had progressed 
to severe organ damage (i.e. Vasculitis Damage Index (VDI) score of ≥ 5) (6). Additionally, 
results from the MAINRITSAN2 randomised controlled trial demonstrated AAV relapse rates 
did not differ significantly between individually tailored and fixed-schedule RTX regimens at 
28 months and with fewer RTX cycles using the former strategy (7).  
Although the rate for IGRT was the lowest in RA, we agree this is not a reason to be complacent 
since patients with RA need more frequent cycles for life-long therapy with median duration 
of response to RTX in RA, SLE and AAV were 10 months (8), 12 months (9) and 18 months 
(6) respectively. In those with low IgG either at baseline or at ≥4 months’ duration of RTX 
therapy (N=110), there were 10/110 (9.1%) infection-associated deaths. Moreover, only 4/11 
(36%) RA patients had their IgG normalized after at least 2 years post-bDMARDs switch, thus 
posing a treatment dilemma in the management of difficult to treat RA from the perspective of 
infection once RTX is discontinued (1). Therefore, our data strongly advocate that regardless 
RMD diagnoses, immunoglobulin levels should be monitored at baseline and before each RTX 
cycle, particularly in patients with comorbidities and low baseline immunoglobulin levels, in 
order to discern those at risk of serious infection events (SIEs).  
Lastly, we agree with Karim MY that measurement of specific antibody responses to tetanus, 
hemophilus and pneumococcus should be measured more widely in clinical practice in patients 
with low IgG and/or an SIE in the previous RTX cycle in order to facilitate effective pre-RTX 
vaccination, as well as to identify those who fail to response after an appropriate vaccination 
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